Skip to main content

COR

Stock
Health Care
Medical Distribution

Performance overview

COR Price
Price Chart

Forward-looking statistics

Beta
0.35
Risk
18.21%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Company info

SectorHealth Care
IndustryMedical Distribution
Employees29K
Market cap$46.4B

Fundamentals

Enterprise value$66.1B
Revenue$310.2B
Revenue per employee
Profit margin0.55%
Debt to equity827.73

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$8.65
Dividend per share$2.20
Revenue per share$1,586.71
Avg trading volume (30 day)$408M
Avg trading volume (10 day)$477M
Put-call ratio

Macro factor sensitivity

Growth+2.5
Credit+0.6
Liquidity+0.1
Inflation-0.7
Commodities+0.4
Interest Rates-0.5

Valuation

Dividend yield0.74%
PEG Ratio18.11
Price to sales0.19
P/E Ratio18.11
Enterprise Value to Revenue0.21
Price to book56.67

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend dayMay 16, 2025

News

Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 11, 2025)
CoreWeave CEO on Integrating Core Scientific

CoreWeave CEO Michael Intrator details the purchase of Core Scientific for $9 billion, saying it's part of a strategy to get "to scale" as AI demand growth continues. He joins Caroline Hyde on "Bloomberg Tech" to discuss.

Bloomberg Technology (July 8, 2025)
Core Scientific purchase doesn't add any profits to CoreWeave, says D.A. Davidson's Gil Luria

Gil Luria, DA Davidson head of technology research, joins 'Squawk Box' to discuss the latest deal between CoreWeave and Core Scientific, if it's a smart move and much more.

CNBC Television (July 8, 2025)
CoreWeave Just Valued Core Scientific Like It's 2021 Again

CoreWeave Inc CRWV just made a big move — but the market didn't applaud. Shares of Core Scientific Inc CORZ plunged nearly 21% on Monday, even as AI cloud provider CoreWeave announced it will acquire the Bitcoin BTC/USD miner in an all-stock deal.

Benzinga (July 7, 2025)
CoreWeave to acquire Core Scientific in $9 billion all-stock deal

Artificial intelligence hyperscaler CoreWeave said Monday it will acquire Core Scientific, a leading data center infrastructure provider. It is an all-stock deal valued at approximately $9 billion.

CNBC (July 7, 2025)
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.

Benzinga (May 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free